Moderna shares fell 2.75% to $154.47 in premarket trading and later declined 7% to $148.02 on Wednesday, with no fresh company news cited for the retreat. The decline followed a 14% rally Tuesday after Wolfe Research upgraded the stock to Peer Perform from Underperform and came after a surge of more than 150%; shares had gained 439% year to date and 194% over the previous month through Tuesday’s close. The move was sharper than declines in BioNTech and biotechnology benchmarks, indicating pressure was largely specific to Moderna. Investors are weighing the company’s roughly $59 billion valuation against second-quarter 2026 revenue of $145 million, a $1.97-per-share loss and a $782 million net loss. The bullish case centers on intismeran, Moderna and Merck’s personalized mRNA cancer therapy, whose Phase 3 INTerpath-001 trial met its recurrence-free-survival and distant-metastasis-free-survival endpoints and became the first successful Phase 3 validation for an individualized mRNA cancer treatment. Wolfe Research estimated $9.2 billion in unadjusted peak sales across four indications, while Moderna’s valuation remains dependent on the program’s future development and approval prospects.